- Earlier this week AbbVie reported positive topline Phase 3 CERVINO results for etentamig, a BCMA x CD3 bispecific T‑cell engager, showing higher objective response rates and improved progression‑free survival versus standard therapies in triple‑class exposed relapsed/refractory multiple myeloma, with a manageable safety profile and monthly dosing after a single step‑up dose.
- The trial’s combination of strong efficacy, low rates of cytokine release syndrome and infections, and outpatient‑friendly monthly dosing positions etentamig as a potentially differentiated option in an increasingly crowded myeloma treatment field, pending regulatory review.
- We’ll now examine how etentamig’s Phase 3 success and convenient monthly dosing could influence AbbVie’s broader investment narrative and pipeline outlook.
We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
AbbVie Investment Narrative Recap
To own AbbVie today, you generally need to believe it can offset Humira’s erosion with newer immunology, neuroscience and oncology drugs while managing debt and pricing pressure. Etentamig’s strong Phase 3 data adds another potential oncology pillar, but as an unapproved asset it does not yet change the near term focus on Skyrizi and Rinvoq execution as key upside catalysts, or the risk that concentrated product exposure and tighter drug pricing could weigh on future earnings.
The most relevant recent update alongside etentamig is AbbVie’s guidance raise to about US$67.6 billion in 2026 revenue, which highlights how existing franchises are carrying the financial load while the oncology pipeline matures. Against that backdrop, the EMA filing for subcutaneous Skyrizi induction in Crohn’s disease and other late stage immunology and oncology readouts may matter more to AbbVie’s medium term story than any single early launch in myeloma.
Yet behind the positive trial headlines, investors should be aware of the concentration risk if future safety issues or competitor advances hit AbbVie’s core immunology and neuroscience franchises...
Read the full narrative on AbbVie (it's free!)
AbbVie’s narrative projects $81.5 billion revenue and $24.6 billion earnings by 2029. This requires 8.2% yearly revenue growth and about an $18.3 billion earnings increase from $6.3 billion today.
Uncover how AbbVie's forecasts yield a $273.39 fair value, a 5% upside to its current price.
Exploring Other Perspectives
Three fair value estimates from the Simply Wall St Community span roughly US$273 to US$452 per share, showing how far apart individual views can be. When you set those against the company’s reliance on a focused immunology and neuroscience portfolio, it underlines why many investors look at several different opinions before deciding how resilient AbbVie’s long term performance might be.
Explore 3 other fair value estimates on AbbVie - why the stock might be worth just $273.39!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your AbbVie research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
- Our free AbbVie research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbbVie's overall financial health at a glance.
Seeking Other Investments?
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
- Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
- Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Find 52 companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com